Navigation Links
Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Date:1/22/2013

SEATTLE, Jan. 22, 2013 /PRNewswire/ -- TapImmune Inc. (OTCBB: TPIV) is pleased to announce the January publication of a paper titled "Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T-cells", authored by Henle et al, J.Immunol. (2013), 190, 479-488.  This work, performed in the laboratory of Dr Keith Knutson at Mayo Clinic, describes the discovery of a novel HER-2/neu Class I epitope (p373-382) TapImmune has licensed from Mayo Clinic for the development of breast cancer vaccines.  The significance of this work is that this newly discovered antigen is a naturally occurring antigen processed by the proteasome and elicits peptide-specific T-cell responses.  This results in stronger binding to HLA-A2 and more efficient killing of HER-2/neu positive breast cancer cells by activated T-cells compared to the Class I epitope, p369-377 (E75) which was not naturally processed by the proteasome.

"These results provide an explanation of the molecular immunology behind our approach to HER-2/neu immunotherapy," said Mark Reddish Vice President of TapImmune Inc.  "These data describe how the HER-2/neu protein is processed by the proteasome to then be presented for immune recognition and killing.  By revealing the true identity of the immunodominant epitope responsible for class I mediated killing of HER-2/neu positive tumors, it is now possible to generate a true second generation vaccine that incorporates the correct target as it naturally appears on human tumors.  For nearly 20 years the immunology of this key protein has been clouded by contradictory observations, and these data finally provide an understanding of the 'natural target' displayed on human tumors. We expect to combine this immunodominant peptide with our broadly reactive helper peptides that are currently being tested in a phase I trial, to create a tru
'/>"/>

SOURCE TapImmune Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Report Details NCPA Efforts to Drive Greater Medication Adherence
2. ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
3. CoLucid Pharmaceuticals Details Phase 3 Development Strategy for Lasmiditan to Address Major Unmet Needs in Acute Migraine Therapy
4. Young Innovations, Inc. Provides 2nd Quarter Conference Call Details
5. CryoLife Announces Release Date and Teleconference Call Details for 2012 Second Quarter Financial Results
6. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
7. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
8. Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma, Inc.
9. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
10. Barrack, Rodos & Bacine Files Class Action Lawsuit Against St. Jude Medical, Inc.
11. Thomson Reuters Empowers Drug Development and Clinical Professionals to Develop Better, Faster Clinical Trials with Best-in-Class Intelligence Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)...   TRU-D SmartUVC LLC, producers of the ... today that the General Services Administration has awarded the ... This newly formed agreement will allow TRU-D ... purchasers, including Department of Veteran Affairs and Department of ... purchasing solutions for the Ebola effort in ...
(Date:12/22/2014)... 2014  ConvaTec, a privately-held medical products and technologies ... Interim Chief Executive Officer of the company, effective December ... Berger .  "The Board of Directors of ConvaTec thanks ... the past three years," said Magnus Lundberg , ... confident that the company is well positioned for the ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... Dimes Publishes Findings in Nature Medicine, WHITE PLAINS, ... study of pre-eclampsia, a serious and potentially deadly,disorder that ... in mice that may have important implications for diagnosis,and ... Rodney E. Kellems, Ph.D., Department of,Biochemistry and Molecular Biology; ...
... NEW YORK, July 28 Polyphenon Pharma, an ... and,Drug Administration (FDA) has granted Orphan Drug Designation ... of chronic lymphocytic,leukemia (CLL). A Phase II study ... Minnesota where researchers are studying the effects of ...
Cached Medicine Technology:New Research on Pre-Eclampsia in Mice May Have Important Implications for Humans 2Polyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of CLL 2
(Date:12/21/2014)... By Dennis Thompson ... -- Former tobacco smokers find e-cigarettes less addictive than traditional ... e-cigarettes as often as they did regular cigarettes, thousands of ... to feel impulsive and irritable over their need to smoke, ... clear. The score was significantly less for e-cig use than ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... (PRWEB) December 21, 2014 Serious Buyer, ... for Vintage 1967 Jm Morrison and the Doors International Ballroom ... This would also be the only time that Morrison's ... was on Nov. 25, 1967. According to Hawley, “This ... They did play the Alexandria Roller Rink earlier that ...
(Date:12/21/2014)... CA (PRWEB) December 21, 2014 Over ... resolved performance issues in hundreds of emergency departments across ... satisfaction. Its findings have been translated into an innovative ... leaders to correct deficiencies and enhance the patient experience. ... outsourced emergency physician staffing and management services for hospitals, ...
(Date:12/21/2014)... December 21, 2014 Theme ... a new intro plugin for Final Cut Pro X ... videos, logos, and more with absolute ease.” Said Christiana ... users the tools needed to easily animate their media ... Cut Pro X users to animate pictures, videos, logos, ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... Lvov, a chemistry professor in Louisiana Techs Institute for ... the Year, beating candidates from Princeton University and companies ... in the journals January 2008 issue. , Lvov received ... cancer drugs. His research pioneers drug reformulation through polyelectrolyte ...
... YORK, Dec. 5 At a briefing ... vice president -- DuPont,Performance Materials, discussed the ... $6 billion in annual sales, the DuPont,Performance ... value-added applications development for the global,packaging, transportation, ...
... event of its kind in the country, provides ... healing and other resources, ... District, is hosting the fourth,Breaking The Silence 2007: A Summit on ... - 8 p.m. and Saturday,December 8, 8 a.m. - 3 p.m. ...
... Protalix,BioTherapeutics, Inc. (Amex: PLX ), announced today ... Jane H. Hsiao, Ph.D., have resigned from,the Company,s ... reasons. Dr. Hsiao was a member of the ... Protalix BioTherapeutics, Inc., Protalix is a biopharmaceutical ...
... As companies transform their,call centers into service-to-sales operations, ... while maintaining a customer service,function. Because they play ... is one of the key factors behind a ... leaders recommend reducing spans of control by as,much ...
... Resources to Coordinate Care, NEWTON, Mass., Dec. ... as a major cause of stress and functional ... in America are in a,silent crisis; overwhelmed by ... or elderly family member. These families face a,multitude ...
Cached Medicine News:Health News:Louisiana Tech professor is Small Times' Innovator of the Year 2Health News:DuPont Group Vice President Briefs Investors on Performance Materials Segment 2Health News:Actress Jenifer Lewis, Authors Dr. Michael Eric Dyson and Susan Taylor Among Featured Speakers for Senator Hughes' Behavioral Mental Health Summit 2Health News:Protalix BioTherapeutics Announces Resignation of Board Members 2Health News:Managing the Service-to-Sales Cultural Transformation - Complimentary Excerpt Available from Best Practices 2Health News:Family Caregivers in Crisis Have New Hope 2
Fine 3.0 mm platformed angled 60 degrees 10 mm from angle to tip. Serrated handle with dull finish....
Tennant straight tying forceps, 6.0 mm tying platforms, with pin, extra delicate smooth jaws....
Sinskey tying forceps, straight, fine, 7 mm tying platforms....
O'Gawa-Castroviejo tying forceps, straight shafts, 6 mm tying platforms, wide handle....
Medicine Products: